Evaluating the Efficacy of Doxorubicin-Trabectedin Combination Therapy in Metastatic Leiomyosarcoma
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on October 23rd, 2024
|
Leiomyosarcoma is a prevalent type of soft tissue sarcoma with a poor prognosis following metastasis. While doxorubicin is the standard first-line treatment, previous studies have shown that combining it with other agents does not improve clinical outcomes. Trabectedin, a second-line therapy, is typically used to manage disease progression after metastasis. Recently, a study sponsored by PharmaMar investigated whether adding trabectedin to the first-line treatment with doxorubicin could improve outcomes in managing leiomyosarcoma.
A phase 3 clinical trial conducted in France included 150 participants diagnosed with leiomyosarcoma, with 90% having metastasized, primarily to the lungs and liver. The participants were randomly assigned to receive either the standard treatment of doxorubicin alone or a combination therapy of doxorubicin and trabectedin. In the monotherapy group, doxorubicin was administered intravenously at 75 mg/m² every 3 weeks. For the combination group, the doxorubicin dose was reduced to 60 mg/m², and trabectedin was given at 1.1 mg/m² every 3 weeks. Both groups received colony-stimulating factors treatment: lenograstim (150 μg/m² on days 3 and 9) in the monotherapy group, and pegfilgrastim (6 mg on day 2) in the combination group. Treatment was stopped after 6 cycles, though the combination group continued with trabectedin alone for an additional 17 cycles. After a median follow-up of 55 months, the median survival in the combination therapy group was 33 months, compared to 24 months in the monotherapy group, representing a 35% reduction in the risk of death. However, the combination therapy group experienced a higher rate of adverse events, including increased neutropenia, anemia, thrombocytopenia, and febrile neutropenia, leading to more frequent dose reductions.
A phase 3 clinical trial conducted in France included 150 participants diagnosed with leiomyosarcoma, with 90% having metastasized, primarily to the lungs and liver. The participants were randomly assigned to receive either the standard treatment of doxorubicin alone or a combination therapy of doxorubicin and trabectedin. In the monotherapy group, doxorubicin was administered intravenously at 75 mg/m² every 3 weeks. For the combination group, the doxorubicin dose was reduced to 60 mg/m², and trabectedin was given at 1.1 mg/m² every 3 weeks. Both groups received colony-stimulating factors treatment: lenograstim (150 μg/m² on days 3 and 9) in the monotherapy group, and pegfilgrastim (6 mg on day 2) in the combination group. Treatment was stopped after 6 cycles, though the combination group continued with trabectedin alone for an additional 17 cycles. After a median follow-up of 55 months, the median survival in the combination therapy group was 33 months, compared to 24 months in the monotherapy group, representing a 35% reduction in the risk of death. However, the combination therapy group experienced a higher rate of adverse events, including increased neutropenia, anemia, thrombocytopenia, and febrile neutropenia, leading to more frequent dose reductions.